Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.